PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-51.66%
Negative revenue growth while CVE stands at 34.35%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-93.69%
Negative gross profit growth while CVE is at 629.36%. Joel Greenblatt would examine cost competitiveness or demand decline.
-226.72%
Negative EBIT growth while CVE is at 112.64%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-226.72%
Negative operating income growth while CVE is at 112.64%. Joel Greenblatt would press for urgent turnaround measures.
-58.58%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-57.78%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-58.74%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.51%
Share change of 0.51% while CVE is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
No Data
No Data available this quarter, please select a different quarter.
-15.81%
Dividend reduction while CVE stands at 2.44%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
-47.13%
Negative OCF growth while CVE is at 12.64%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
34.65%
FCF growth under 50% of CVE's 72.34%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
-90.63%
Both companies have negative long-term revenue/share growth. Martin Whitman would question if the entire market or product set is shrinking.
-84.06%
Both face negative 5Y revenue/share CAGR. Martin Whitman would suspect macro headwinds or obsolete product offerings across the niche.
-84.05%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
-96.50%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-92.50%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-86.97%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-127.28%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-397.03%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-171.59%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-73.41%
Negative equity/share CAGR over 10 years while CVE stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-74.88%
Negative 5Y equity/share growth while CVE is at 19.66%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-19.61%
Negative 3Y equity/share growth while CVE is at 6.91%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
-86.86%
Cut dividends over 10 years while CVE stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-93.49%
Both lowered dividends mid-term. Martin Whitman might suspect broad sector constraints or strategic shifts from dividends.
-91.14%
Both firms reduced dividends recently. Martin Whitman suspects broader macro or industry issues forcing cost and payout cuts.
3.27%
AR growth is negative/stable vs. CVE's 27.84%, indicating tighter credit discipline. David Dodd confirms it doesn't hamper actual sales.
No Data
No Data available this quarter, please select a different quarter.
-1.82%
Negative asset growth while CVE invests at 0.87%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-11.31%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
3.77%
Debt growth far above CVE's 0.31%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
-12.36%
We cut SG&A while CVE invests at 56.67%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.